FindTrial
Sign In

Double-blind comparative study of TAK-875

-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221774
Enrollment
Unknown
Registered
2012-04-23
Start date
2012-04-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

investigational material(s) Generic name etc : TAK-875 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : p

Sponsors

TAKEDA PHARMACEUTICAL COMPANY LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The subject is an outpatient. 2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

Exclusion criteria: 1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease. 2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026